{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:30:33Z","timestamp":1786977033224,"version":"build-2736575974"},"reference-count":33,"publisher":"The Endocrine Society","issue":"2","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Fibroblast growth factor (FGF23) is a phosphate-regulating hormone and might be a biomarker of cardiorenal comorbidities in the general population. Its role in hypoparathyroidism is unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the prevalence of abnormal FGF23 concentrations in patients with chronic hypoparathyroidism and explore their associations with mineral metabolism and renal phosphate handling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Cross-sectional, observational study complemented by a retrospective longitudinal analysis of biochemical parameters over a median follow-up of 5 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients<\/jats:title>\n                    <jats:p>Forty-eight consecutive patients with chronic hypoparathyroidism (mean age 60.6 \u00b1 16.3 years; 85% women; 87.5% postsurgical) evaluated at an academic medical center between January 2023 and December 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements<\/jats:title>\n                    <jats:p>Serum intact FGF23 levels, serum calcium (Ca) and phosphate (P), Ca \u00d7 P product, PTH, 1,25-dihydroxyvitamin D [1,25(OH)2D], estimated glomerular filtration rate (eGFR), and renal phosphate reabsorption [maximum rate of renal tubular reabsorption of phosphate\/glomerular filtration rate (TmPO4\/GFR)].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Elevated FGF23 levels were found in 71% of patients (mean 157.9 \u00b1 92.4\u2005pg\/mL; reference range 23.2-95.4), despite adequate biochemical control (calcium 8.7 \u00b1 0.8\u2005mg\/dL; phosphate 4.5 \u00b1 0.8\u2005mg\/dL; Ca \u00d7 P product 39.2 \u00b1 6.8\u2005mg\u00b2\/dL\u00b2). FGF23 was associated with longer disease duration (P = .004), lower eGFR (P = .008), lower PTH (P = .03), reduced 1,25(OH)2D (P = .016), and elevated Ca \u00d7 P product (P = .036). Despite elevated FGF23, TmPO4\/GFR was paradoxically increased, suggesting impaired renal responsiveness. Female sex and Ca \u00d7 P product were independent predictors of FGF23 levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>FGF23 is frequently elevated in chronic hypoparathyroidism, indicating a disrupted phosphate metabolism, and its increase seems to be ineffective in promoting phosphate excretion, probably due to renal resistance mechanisms. Further studies are needed to clarify the role of FGF23 as a clinical biomarker, risk factor, and potential therapeutic target in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/jendso\/bvaf217","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T12:59:35Z","timestamp":1766062775000},"source":"Crossref","is-referenced-by-count":1,"title":["Elevated FGF23 Despite Biochemical Control Reveals Hidden Mineral Dysregulation in Chronic Hypoparathyroidism"],"prefix":"10.1210","volume":"10","author":[{"given":"Matteo","family":"Malagrin\u00f2","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna 40138 ,","place":["Italy"]},{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna , Bologna 40138 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Piazza","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna 40138 ,","place":["Italy"]},{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna , Bologna 40138 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3202-3300","authenticated-orcid":false,"given":"Nicol\u00f2","family":"Bisceglia","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna 40138 ,","place":["Italy"]},{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna , Bologna 40138 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Capra","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna 40138 ,","place":["Italy"]},{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna , Bologna 40138 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Cantone","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna 40138 ,","place":["Italy"]},{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna , Bologna 40138 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4182-3110","authenticated-orcid":false,"given":"Uberto","family":"Pagotto","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna 40138 ,","place":["Italy"]},{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna , Bologna 40138 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3657-2070","authenticated-orcid":false,"given":"Guido","family":"Zavatta","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna 40138 ,","place":["Italy"]},{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna , Bologna 40138 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,12,20]]},"reference":[{"issue":"3","key":"2026012904163609600_bvaf217-B1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/81664","article-title":"Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23","volume":"26","author":"White","year":"2000","journal-title":"Nat Genet"},{"issue":"11","key":"2026012904163609600_bvaf217-B2","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1073\/pnas.101545198","article-title":"Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia","volume":"98","author":"Shimada","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2026012904163609600_bvaf217-B3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41581-022-00665-x","article-title":"Regulation of FGF23 production and phosphate metabolism by bone\u2013kidney interactions","volume":"19","author":"Agoro","year":"2023","journal-title":"Nat Rev Nephrol"},{"issue":"19","key":"2026012904163609600_bvaf217-B4","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1161\/CIRCULATIONAHA.108.844506","article-title":"Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease","volume":"119","author":"Guti\u00e9rrez","year":"2009","journal-title":"Circulation"},{"issue":"2","key":"2026012904163609600_bvaf217-B5","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1681\/ASN.2013050465","article-title":"Fibroblast growth factor-23 and cardiovascular events in CKD","volume":"25","author":"Scialla","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"2026012904163609600_bvaf217-B6","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1681\/ASN.2006080936","article-title":"Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the mild to moderate kidney disease (MMKD) study","volume":"18","author":"Fliser","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"16","key":"2026012904163609600_bvaf217-B7","doi-asserted-by":"crossref","first-page":"e145693","DOI":"10.1172\/JCI145693","article-title":"Calcium phosphate microcrystals in the renal tubular fluid accelerate chronic kidney disease progression","volume":"131","author":"Shiizaki","year":"2021","journal-title":"J Clin Invest"},{"issue":"10","key":"2026012904163609600_bvaf217-B8","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.1210\/jc.2016-2215","article-title":"Fibroblast growth factor 23 and cause-specific mortality in the general population: the northern Manhattan study","volume":"101","author":"Souma","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2026012904163609600_bvaf217-B9","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1002\/jbmr.483","article-title":"Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research","volume":"26","author":"Bilezikian","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2026012904163609600_bvaf217-B10","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1007\/s12325-021-01787-7","article-title":"Risk of cardiovascular conditions in patients with chronic hypoparathyroidism: a retrospective cohort study","volume":"38","author":"Gosmanova","year":"2021","journal-title":"Adv Ther"},{"issue":"4","key":"2026012904163609600_bvaf217-B11","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/cen.14872","article-title":"Coronary artery disease and its vascular associates in patients with chronic nonsurgical hypoparathyroidism","volume":"98","author":"Saha","year":"2023","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2026012904163609600_bvaf217-B12","doi-asserted-by":"crossref","first-page":"e4004","DOI":"10.1210\/clinem\/dgaf257","article-title":"Increased risk of cardiovascular diseases in patients with chronic hypoparathyroidism in Sweden","volume":"28","author":"Bj\u00f6rnsdottir","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026012904163609600_bvaf217-B13","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.surg.2024.05.005","article-title":"Long-term kidney outcomes in patients with permanent hypoparathyroidism after total thyroidectomy for benign disease: a population-based study","volume":"176","author":"Luk","year":"2024","journal-title":"Surgery"},{"issue":"4","key":"2026012904163609600_bvaf217-B14","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1007\/s12325-021-01658-1","article-title":"Risk of chronic kidney disease and estimated glomerular filtration rate decline in patients with chronic hypoparathyroidism: a retrospective cohort study","volume":"38","author":"Gosmanova","year":"2021","journal-title":"Adv Ther"},{"issue":"9","key":"2026012904163609600_bvaf217-B15","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1210\/jc.2004-0724","article-title":"FGF-23 is elevated by chronic hyperphosphatemia","volume":"89","author":"Gupta","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026012904163609600_bvaf217-B16","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/jbmr.4429","article-title":"PTH and FGF23 exert interdependent effects on renal phosphate handling: evidence from patients with hypoparathyroidism and hyperphosphatemic familial tumoral calcinosis treated with synthetic human PTH 1\u201334","volume":"37","author":"Ovejero","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2026012904163609600_bvaf217-B17","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12882-020-01826-5","article-title":"Interaction between serum FGF-23 and PTH in renal phosphate excretion, a case-control study in hypoparathyroid patients","volume":"21","author":"Saki","year":"2020","journal-title":"BMC Nephrol"},{"issue":"7","key":"2026012904163609600_bvaf217-B18","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1210\/clinem\/dgab114","article-title":"Alfacalcidol vs calcitriol in the management of patient with hypoparathyroidism: a randomized controlled trial","volume":"106","author":"Saha","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026012904163609600_bvaf217-B19","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s40618-022-01770-1","article-title":"Hyperphosphatemia is associated with cardiac valve calcification in chronic hypoparathyroidism","volume":"45","author":"Polonine","year":"2022","journal-title":"J Endocrinol Invest"},{"issue":"12","key":"2026012904163609600_bvaf217-B20","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1002\/jbmr.4691","article-title":"Evaluation and management of hypoparathyroidism summary statement and guidelines from the second international workshop","volume":"37","author":"Khan","year":"2022","journal-title":"J Bone Miner Res"},{"key":"2026012904163609600_bvaf217-B21","author":"Matteo"},{"issue":"5","key":"2026012904163609600_bvaf217-B22","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1053\/j.ajkd.2011.06.011","article-title":"Relation of sex and estrogen therapy to Serum fibroblast growth factor 23, Serum phosphorus, and urine phosphorus: the heart and soul study","volume":"58","author":"Ix","year":"2011","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"2026012904163609600_bvaf217-B23","doi-asserted-by":"crossref","first-page":"e0268759","DOI":"10.1371\/journal.pone.0268759","article-title":"Associations between endogenous sex hormones and FGF-23 among women and men in the multi-ethnic study of atherosclerosis","volume":"17","author":"Ogunmoroti","year":"2022","journal-title":"PLoS One"},{"issue":"3","key":"2026012904163609600_bvaf217-B24","doi-asserted-by":"crossref","first-page":"BSR20231380","DOI":"10.1042\/BSR20231380","article-title":"The molecular sociology of NHERF1 PDZ proteins controlling renal hormone-regulated phosphate transport","volume":"44","author":"Friedman","year":"2024","journal-title":"Biosci Rep"},{"issue":"36","key":"2026012904163609600_bvaf217-B25","doi-asserted-by":"crossref","first-page":"18632","DOI":"10.1074\/jbc.M116.744052","article-title":"Convergent signaling pathways regulate parathyroid hormone and fibroblast growth factor-23 action on NPT2A-mediated phosphate transport","volume":"291","author":"Sneddon","year":"2016","journal-title":"J Biol Chem"},{"issue":"1","key":"2026012904163609600_bvaf217-B26","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s12020-025-04221-y","article-title":"Obesity and blunted FGF23 response associate with kidney impairment in patients with hypoparathyroidism","volume":"89","author":"di Filippo","year":"2025","journal-title":"Endocrine"},{"issue":"4","key":"2026012904163609600_bvaf217-B27","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/jbmr.263","article-title":"Serum fibroblast growth factor-23 (FGF-23) and fracture risk in elderly men","volume":"26","author":"Mirza","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2026012904163609600_bvaf217-B28","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1002\/jbmr.1985","article-title":"Association of serum fibroblast growth factor 23 (FGF23) and incident fractures in older men: the osteoporotic fractures in men (MrOS) study","volume":"28","author":"Lane","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2026012904163609600_bvaf217-B29","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1210\/jc.2013-1152","article-title":"Fibroblast growth factor 23, bone mineral density, and risk of hip fracture among older adults: the cardiovascular health study","volume":"98","author":"Jovanovich","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"19","key":"2026012904163609600_bvaf217-B30","doi-asserted-by":"crossref","first-page":"17291","DOI":"10.18632\/oncotarget.4174","article-title":"FGF23 promotes prostate cancer progression","volume":"6","author":"Feng","year":"2015","journal-title":"Oncotarget"},{"issue":"11","key":"2026012904163609600_bvaf217-B31","doi-asserted-by":"crossref","first-page":"e3745","DOI":"10.1210\/clinem\/dgaf138","article-title":"Platelet function and markers of atherothrombotic risk in subjects with parathyroid disorders: a cross-sectional study","volume":"110","author":"Naciu","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026012904163609600_bvaf217-B32","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/ki.2012.327","article-title":"Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community","volume":"83","author":"\u00c4rnl\u00f6v","year":"2013","journal-title":"Kidney Int"},{"issue":"3","key":"2026012904163609600_bvaf217-B33","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jacc.2012.03.040","article-title":"Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (cardiovascular health study)","volume":"60","author":"Ix","year":"2012","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/jendso\/bvaf217\/66043596\/bvaf217.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/10\/2\/bvaf217\/66043596\/bvaf217.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/10\/2\/bvaf217\/66043596\/bvaf217.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T09:16:46Z","timestamp":1769678206000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvaf217\/8384648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,20]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,7]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvaf217","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,12,20]]},"article-number":"bvaf217"}}